Venous thromboembolism occurs in up to 25% of cancer patients treated with immunotherapy, according to a recent Cleveland Clinic study.
Venous thromboembolism is markedly higher in patients with COVID-19 in the intensive care unit, but routine screening is not recommended. Shruti Gadre, MD, discusses when to consider testing and how to manage care.
Severe COVID-19 is associated with a hypercoagulable state that often requires changes to usual inpatient anticoagulation strategies. We share our approach, including thromboprophylaxis protocols and a case vignette.
Three in five pregnancy-related deaths in the United States are preventable. Cleveland Clinic obstetrician, Kathleen Berkowitz, MD, explains the protocols the health system has put in place to prevent maternal mortality and respond to obstetric emergencies.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A secondary analysis of the CASSINI trial finds that rivaroxaban is an effective thromboprophylactic for patients with pancreatic cancer receiving systemic therapy.
Two new studies show that oral anticoagulants and prescreening for blood clots before starting cancer treatment may help prevent blood clots in high-risk cancer patients.
Since Alok Khorana, MD, introduced this tool a decade ago, it has been validated multiple times in different countries and incorporated into a number of society guidelines.
Post-operative VTEs can be deadly. A nurse-led study at Cleveland Clinic compared the effectiveness of written instructions versus a multimethod educational approach to teach patients about VTEs.
The rate of VTE recurrence in patients with GPA is similar to that of first VTE recurrence in patients with cancer.
With an array of VTE chemoprophylactic agents – from low-molecular-weight heparin to warfarin to newer anticoagulants – available for patients undergoing TJA, how do you choose? Is simple ASA enough?